RAISE Act

Bill: 117-hr-2934
Sponsor: full_name: Rep. O'Halleran, Tom [D-AZ-1]
Introduced: 2021-04-30
Policy area: Health
Subjects: Blood and blood diseases

Digestive and metabolic diseases

Health care coverage and access

Medicare

Prescription drugs
Latest action: action_date: 2021-05-03
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2021-04-30
action_desc: Introduced in House
text: <p><b>Renal Anemia Innovation Support and Expansion Act or the RAISE Act</b></p> <p>This bill allows coverage of prescription vitamin and mineral products under the Medicare prescription drug benefit if the products are administered orally and are used to treat iron deficiency anemia in individuals who have chronic kidney disease.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 2934 IN THE HOUSE OF REPRESENTATIVES April 30, 2021 Mr. O'Halleran (for himself, Mr. Bucshon , Mr. Butterfield , and Mr. Mullin ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to remove from the list of drugs excluded from coverage under the Medicare prescription drug program prescription oral vitamins and mineral products indicated for the treatment of iron deficiency anemia in individuals with chronic kidney disease.

1. Short title This Act may be cited as the Renal Anemia Innovation Support and Expansion Act or the RAISE Act . 2. Removing certain prescription vitamins and mineral products from the list of drugs excluded from coverage under the Medicare prescription drug program Section 1860D–2(e)(2)(A) of the Social Security Act ( 42 U.S.C. 1395w–102(e)(2)(A) ) is amended by inserting other than subparagraph (F) of such section (relating to prescription vitamin and mineral products, except prenatal vitamins and fluoride preparations) if the prescription vitamin or mineral product is orally administered and is indicated for treatment of iron deficiency anemia in individuals with chronic kidney disease, after other than subparagraph (E) of such section (relating to smoking cessation agents), .